A Phase Ⅱ Clinical Study Trial of Felbinac Trometamol Injection in China

Inclusion Criteria: * 18≤age≤65 years of age, gender is not limited; * ASA grade I or II; * 18 ≤ body mass index (BMI) ≤ 30 \[BMI = weight (kg) / height 2 (m2)\]; * Inpatients who underwent open surgery under elective general anesthesia (including gallbladder, intestinal or lower abdominal surgery, etc.), or laparoscopic surgery with a single surgical incision ≥ 5 cm; * Expected to require more than 24 hours of PCIA( patient controlled intravenous analgesia) treatment after surgery ; * Ability to understand research procedures and pain scales, operate PCIA devices, and communicate effectively with researchers; * Agree to participate in the trial and voluntarily sign the informed consent form. Exclusion Criteria: * Those who have a history of chronic pain for more than 3 months or who are undergoing regular analgesia for more than 3 months; * Those who used other analgesics, muscle relaxants or sedatives within 24 hours before operation (excluding those required for this operation), or those who used long-acting non-steroidal anti-inflammatory drugs (NSAIDs) within 12 hours, or those who used short-acting non-steroidal anti-inflammatory drugs (NSAIDs) within 6 hours before operation(See Annex 1). * A person with high bleeding risk, and also including who with congenital bleeding disorders (such as hemophilia), thrombocytopenia (PLT \< 80 × 10 ∧ 9 / L), abnormal platelet function (such as idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet dysfunction, etc.) or any clinically significant active bleeding, coagulopathy; * A person who received full-dose anticoagulant therapy, activated protein C or thrombolytic drugs within 6 hours before surgery (except for heparin subcutaneous injection for preventive treatment); * People with heart failure (NYHA grade III or IV), unstable angina pectoris, acute myocardial infarction, and severe arrhythmia within 6 months before surgery * Hypertensive patients who have not been satisfactorily controlled by blood pressure (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥105mmHg), or ACEI/diuretics for ≥30 days, or hypotension (systolic blood pressure \<90mmHg); * People with bronchial asthma, pulmonary heart disease or other serious respiratory diseases; * Person with gastrointestinal ulcer and a history of gastrointestinal bleeding 6 weeks before operation and required medical treatment; * Those with previous cerebral arteriovenous malformations, cerebral aneurysms, brain tumors, or preoperative traumatic brain injury, intracranial surgery, history of stroke; * Patients with poor glycemic control of diabetes (random blood glucose \> 11.1mmol / L); * Patients with autoimmune diseases, connective tissue diseases, etc. who need long-term use of adrenocortical hormone therapy; * Abnormal liver and kidney function: ALT/AST\> 2 times the upper limit of normal value, or creatinine\> upper limit of normal value, or dialysis treatment within 28 days before surgery; * Allergic constitution, or known to be allergic to this drug, NSAIDs, and opioids; * Patients who are afflicted with narcotic drugs, drugs, or resistant to opioids; * A woman who is breast-feeding or pregnant, who is unable or unwilling to follow the investigator's guidance during the study period and within 3 months after the last study treatment; * Those who have participated in other clinical trials within 3 months before surgery; * Investigators believe that it is not suitable for participating in this research.